GU Cancer

Explore the most recent news and cutting-edge research in genitourinary (GU) cancer. Cancer Nursing Today reports on the latest clinical updates affecting the urinary tract and male reproductive system. Discover how the newest trials and research are changing the GU cancer care landscape for clinicians and patients.

Reviewing Adjuvant Therapies for Localized RCC
The use of immune checkpoint inhibitors for the treatment of localized renal cell carcinoma (RCC) has evolved over the past several years, with drugs such as nivolumab and pembrolizumab becoming approved for treatment use. Localized RCC can be cured through surgery, but many patients may need additional treatment in the form of immune checkpoint inhibitors as adjuvant therapy. A recent study looks at previous adjuvant therapy treatments to determine the future of adjuvant therapy use for localized RCC. ...
Advertisement

Latest News

Advertisement

Knowledge Hubs

GI Cancer
GI Cancer

Conference Highlights

Cecilia BrownConferences | October 5, 2022
The GVHD rate was around 5% in patients receiving Orca-T, a high-precision, regulatory T-cell-engineered donor product.
Read More
Cecilia BrownConferences | October 5, 2022
GVHD occurred more with a fludarabine-based flipped conditioning regimen than with a cyclophosphamide-based flipped regimen.
Cecilia BrownConferences | October 5, 2022
The presence and number of clonal plasma cells in an autograft are predictive of posttransplant outcomes in multiple myeloma.
Cecilia BrownConferences | October 5, 2022
Noncryopreserved and cryopreserved peripheral blood stem cells (PBSC) lead to similar patient outcomes after transplant.
Cecilia BrownConferences | October 5, 2022
Most patients did not have extensive chronic GVHD after a mismatched transplant with this pretransplant conditioning regimen.
Cecilia BrownConferences | October 5, 2022
Patients transplanted with omidubicel had better quality of life than patients transplanted with umbilical cord blood.
Advertisement
Advertisement
Popular Stories